INTRODUCTION
Type 1 diabetes results from selective and progressive destruction of insulin-producing cells by autoreactive CD8 + T cells. 1, 2 The direct cell-cell contact initiated by T-cell receptors recognizing a β-cell-specific antigenic peptide presented by the major histocompatibility complex (MHC) class I (MHC-I) at the surface of the target cell appears to be critical for β-cell destruction in type 1 diabetes. In humans, during acute insulitis, β cells show hyperexpression of MHC-I and selective infiltration by islet-specific autoreactive CD8 + T cells. 3 Also, mice lacking MHC-I expression do not develop diabetes, [4] [5] [6] whereas adoptive spleen cell transfer from NOD mice to recipients selectively expressing MHC-I on β cells leads to β-cell destruction. 7, 8 In addition, the Fas-signaling pathway is not essential in the destruction of β cells, 9, 10 whereas disruption of the perforin gene delays the onset of autoimmune diabetes in NOD mice, pointing to the perforin/granzyme pathway as a key effector in β-cell destruction by cytotoxic T cells. 11, 12 To date, immunotherapies to cure, prevent, or delay disease onset in humans have been inefficient. 13, 14 Options for patients with type 1 diabetes to restore normoglycemia are limited to daily insulin injection, combined kidney-pancreas or experimental islet transplantation. However, numerous factors have been reported to potentially affect islet allograft function and survival. 15 Importantly, the close correlation between loss of islet-graft function and frequencies of circulating autoreactive islet-specific T cells observed in transplanted patients, in particular when the donor and the recipient share the same HLA class I haplotypes, points to the importance of recurrent autoimmunity in islet-graft failure. [16] [17] [18] [19] Along the same line, it appears that, in case of autotransplantation, islet grafts are much less affected, suggesting that persistent attacks from autoimmunity, alloimmunity and possibly the toxicity of immunosuppressive treatments have a major responsibility in graft loss. 20 An alternative could be the transplantation of genetically immunoprotected β cells. We have previously explored the capacity of herpesvirus-derived immunevasins to elude the host immune responses (reviewed in refs. [21] [22] [23] . In this study, we aim to combine the US2 protein of human cytomegalovirus, known to interfere with antigenic peptide presentation by inducing proteasomal degradation of MHC-I molecules, 24 and Serpin-9, a serine protease inhibitor specific for granzyme B activity. 25 Furthermore, the identification of specific human β-cell protectants is hindered by the difficulty of studying the dialogue between human insulin-producing cells and the immune system. Even in vitro, the cellular heterogeneity of dissociated islet preparations makes the standard release-based assays imperfect to specifically assess β-cell cytotoxicity. Islet preparations contain a mixture of cell types, including β cells, α cells, δ cells, ε cells, duct cells, endothelial cells, stem cells, and leukocytes, that all may interfere with the assays to selective assess β-cell cytotoxicity. 26 Here, we describe the development of a new strategy to measure β-cell cytotoxicity and protection from autoreactive T-cellmediated killing. We report that lentivirus vectors can be used to genetically modify human islet cells. Moreover, using this powerful technology, we demonstrate that downregulation of MHC-I combined with the inhibition of granzyme B activity protects human β cells from acute recurrent islet autoimmunity both in vitro and in vivo.
RESULTS

Primary human islet cells can be transduced efficiently by lentiviral vectors
Lentiviral vectors are the gene transfer system of choice for stable genetic modification of primary cells. To evaluate their capacity to genetically modify freshly isolated human islets, a vector Comparative glucose responsiveness of NT islets and GFP-modified islets (GFP) determined by glucose-stimulated insulin-secretion test. Insulin release data are shown as glucose stimulating index (i.e., insulin release at low glucose-white bars-is used as reference and set to 1 and used as reference for high glucose (black bars) induction. (c) Series of optical sections of two representative islets (2 μm) taken by confocal microscopy. Insulin is depicted in red, GFP in green and nuclei are visualized by DAPI (blue) staining. Although some GFP expression could be observed in the central core of the islet (left panel), in most islets GFP expression was limited to the outer rim of the islet (right panel). (d) Fluorescent microscopy picture of GFP-modified pseudoislets (MOI = 2) and quantification of the GFP positive cells by flow cytometry. Light gray histogram shows GFP-transduced cells and non-transduced dispersed cells are shown in dark gray histogram. Experiments are performed 6 days after transduction. (e) Glucose responsiveness of pseudoislets or genetically modified pseudoislets compared with intact islets from the same donor. Similar to b, insulin release data are shown as glucose stimulating index. Low glucose (white bars) concentration is set to 1 and used as reference for high glucose (black bars) induction. GFP, green fluorescent protein; MOI, multiplicity of infection; NT, non-transduced. carrying an enhanced green fluorescent protein (GFP) reporter gene under the control of the human cytomegalovirus immediate early promoter was used (LV-CMV-GFP). Seventy-two hours after transduction, islets were inspected for reporter gene expression (Figure 1a) . A multiplicity of infection of 5 was well tolerated without any apparent signs of virus-induced toxicity. In addition, exposure to the virus did not significantly affect islet function, as exemplified by their capacity to secrete insulin upon glucose stimulation (Figure 1b ). Yet, GFP expression within the islet structures was heterogeneous. Following insulin/DNA staining, whole mount confocal microscopy confirmed that in most islets only cells at the rim of the islets were efficiently transduced, demonstrating that in intact human islets only a limited number of cells are permissive to lentiviral vector transduction (Figure 1c) . To increase the transduction efficiency, human islets were dispersed, and the resulting single-cell suspension was exposed to the lentivirus vector LV-CMV-GFP. Subsequently, pseudoislets were formed by self-aggregation of the transduced cells. Seven days after reaggregation, the 3D structures were macroscopically similar to islets. The majority of the cells expressed GFP as determined by flow cytometry (Figure 1d) . To evaluate the functionality of genetically modified pseudoislet structures, a static glucose-stimulated insulin-secretion test was performed and glucose responsiveness was compared with non-transduced and intact islets. Neither dispersion nor transduction hampered islet functionality, because no differences in insulin release were detected after glucose stimulation (Figure 1e ).
Genetically modified pseudoislets are functional in vivo
To assess the fate of these pseudoislets in vivo, non-transduced and LV-CMV-GFP-transduced human pseudoislets were transplanted under the kidney capsule of NSG mice. The release of human insulin after intraperitoneal glucose administration was measured. Assuming that one islet would contain ~1,000 to 1,500 cells, 27 ~3,000 islet equivalents were transplanted and compared with 5 × 10 6 dispersed/reaggregated cells. Pseudoislets efficiently released insulin upon glucose challenge, because no significant differences were observed when compared with intact islets (Figure 2a) . To define the limitation of the insulin assay used, we transplanted NSG mice with 2.5 × 10 6 cells (~1,500 pseudoislets) or 5 × 10 6 cells (~3,000 pseudoislets) and monitored human insulin release. As anticipated, the amount of insulin secreted correlated with the number of transplanted cells (Figure 2b) . Similar results were obtained with a human C-peptide assay (data not shown).
To confirm the survival of the insulin-producing cells, the graft was removed 19 days after transplantation and analyzed by confocal imaging for GFP fluorescence and, after immunostaining, for insulin reactivity. Macroscopically, a strong and sustained GFP expression was detected at the site of reimplantation (Figure 2c) . Insulin immunostaining demonstrated a large proportion of GFP positive β cells (Figure 2d ). From these data, we conclude that lentivirus-mediated gene transfer into cells from freshly isolated human islets is feasible, and that the cells can be reaggregated to form functional pseudoislets.
The human insulin promoter drives β-cell-specific expression in human islet cells
Next, to acquire specific expression of the gene of choice in β cells, the CMV promoter was replaced by the human insulin promoter (HIP) (Figure 3a) . To assess HIP promoter specificity, we first compared CMV-GFP lentivirus transduction efficiency in human embryonic kidney (HEK) cells or rat insulinoma cell lines (INS-1E) and confirmed that both cell types can be efficiently modified by lentiviruses (Figure 3b , upper panel). Second, we performed similar experiments using the HIP-GFP lentivirus and detected only few GFP positive HEK cells whereas 25% of the INS-1E expressed GFP (Figure 3b , lower panel). Finally, we verified HIP specificity and efficiency in human primary cells. One week after transduction, HIP-GFP human pseudoislets were analyzed for GFP expression using confocal microscopy (Figure 3c) . Altogether, these data demonstrate that the HIP promoter facilitates efficient transgene expression and limits this expression to β cells.
Autoreactive HLA-A2-restricted preproinsulindirected cytotoxic T lymphocyte clones kill HLA-A2 human islet cells in vitro
To quantify β-cell death, the GFP cassette was replaced by a destabilized luciferase reporter gene, allowing short half-life luciferase expression specifically in β cells (Figure 3a) . To validate this method, we designed an in vitro killing assay by incubating HIP-Luc2CPmodified human islet cells with autoreactive CD8 + T cells isolated from a recent onset patient with type 1 diabetes and directed against an epitope located in the signal peptide of the preproinsulin (PPI) molecule. 28 cytotoxic T lymphocyte (CTL) killing capacity was validated in a standard chromium release assay using K562 surrogate β cells ( Supplementary Figure S1 and Supplementary Data).
Using fractions of different purities from the same donor, killing assays were performed with different target/effector ratios (corrected for purity of the fraction). These experiments demonstrate that the luciferase assay is not affected by the quality of the isolated islet fraction (Figure 4a) . Similarly, killing assays performed in parallel with HLA-A2-restricted PPI-directed CTL, incubated with HIP-Luc2CP islet cells from HLA-A3 and HLA-A2 donors, demonstrated that PPI-directed CTL were able to specifically kill HLA-A2 β cells, as seen by a massive drop in luciferase activity. When HLA-A3 donor cells were used as targets, no significant decrease in light emission was observed (Figure 4b) . Moreover, when using HLA-A2-restricted pp65CMV-specific CTL, the viability of the (Figure 4c) , which is consistent with the absence of pp65CMV-target epitope on human β cells. This demonstrates that β-cell death is dependent on the presence of the PPI-specific CTL.
Combined US2/Serpin-9 expression protects surrogate β cells and human primary β cells from PPI-directed CTL killing in vitro
To explore the protective effect of combined MHC-I downregulation and granzyme B inactivation, we generated a bicistronic lentivirus vector encoding the immune-evasion gene US2 and the serine protease inhibitor specific for granzyme B activity (Figure 5a) . First, the protective effect was evaluated on surrogate β cells generated by overexpression of PPI in K562-A2 cells and then transpose to primary human islets. Insulin mRNA level in surrogate β cells was verified by reverse-transcription PCR and quantitative PCR (Figure 5b) . Transduction of K562-A2 with a US2-containing lentivirus vector led to decreased HLA class I expression as quantified by flow cytometry (Figure 5c , lower panel). After transduction of HEK 293T cells at a multiplicity of infection of 1 or 2, the expression of Serpin-9 was verified by western blotting (Figure 5c, upper panel) . Similar results were obtained in primary human islets (Figure 5d) . Following cotransduction of surrogate β cells with CMV-Luc2CP and CMV-DsRed or CMV-US2 lentiviruses, a killing assay was performed with CTLs against PPI. After 48 hours of coculture, massive cell death of DsRed-expressing cells was observed. HLA-A/B/C downregulation mediated by US2 led to protection of the surrogate β cells from PPI-specific CTL killing (Figure 5e) . Importantly, US2/ Serpin-9 coexpression in primary human islets had no effect on insulin release upon glucose stimulation (Supplementary Figure S2a ) and protected human β cells from autoreactive CD8 + T cells as seen by residual luciferase activity after coculture when compared with GFP-modified islets (Figure 5f) .
Primary human β cells can be efficiently immunoprotected from PPI-directed CTL killing in vivo
As an in vivo proof of concept, equal amounts of GFP-or US2/ Serpin-9-modified pseudoislets (~3,000) and PPI-directed CTLs (E:T ratio 1:100) were transplanted under the kidney capsule of NSG mice and human insulin and C-peptide were monitored following intraperitoneal glucose-tolerance tests (Figure 6a,b) . In agreement with the in vitro results, human insulin or C-peptide secretion by GFP pseudoislets was low following cotransplantation with autoreactive CTL. US2/Spi9 expression had no effect on islets functionality (Supplementary Figure S2b) and US2/ Serpin-9 expressing cells maintained both insulin (and C-peptide) secretion, to a level similar to the one measured in absence of autoreactive T cells (Figure 2a,b) , indicating that US2/Serpin-9 expression does not impact on islet viability in vivo and protects β cells from autoimmune CTL attack.
DISCUSSION
Islet transplantation offers a promising approach for restoring endogenous insulin secretion in patients with diabetes. However, recurrent islet autoimmunity has been shown to be a major hurdle thwarting the clinical efficacy of β-cell replacement therapy.
Here, we propose an alternative with transplantation of genetically immunoprotected pseudoislets. We demonstrate that third generation lentiviral vectors can be used as efficient gene carriers for protecting primary human β cells without affecting their function, thereby confirming earlier studies in intact human islets. 29 As described earlier for rodents, 30 the self-aggregation phenomenon of islet cells offers an attractive opportunity to protect these endocrine "micro-organs" to a large extent before transplantation. Although we did not study the precise composition of these pseudoislets in detail, but focused on β cells only, our data show that both treatments (viz. dispersion and transduction) are not accompanied by a significant loss in insulin production rate in response to glucose. These data are in line with a recent study aiming at the evaluation of immunoisolation method and showing that pseudoislets of rat islet cells are superior to primary intact islets in term of survival and function. 31 The luciferase-based survival assay presented here is an alternative to the currently used traditional tracer-release assays, which have their limitations for monitoring cell cultures (reviewed in ref. 32 ). This assay requires a limited number of cells (from 5,000 to 10,000 cells per sample) and the results obtained appeared to be relatively insensitive to variations in the purity of islet preparations. The use of other reporters and substrates (e.g., an amino luciferin derivative specific for caspases 3, 7, 8, or 9) are currently under investigation and may provide new insights into the molecular mechanisms involved in the killing process. 33, 34 The assay relies on the specificity of the promoter: the use of a ubiquitously active promoter to drive luciferase-gene expression in assays to measure β-cell survival was confounded by the increase in luciferase activity due to the expansion of other cell types (data not shown). 26 Besides systemic immunosuppressive injection or immunomodulatory therapy using educated regulatory T cells, 35 other strategies to protect or improve insulin secretion of the transplanted β cells, for example using encapsulated islets, are currently under investigation. However, the perfect material allowing selective permeability and reduced bioreactivity is not available yet (reviewed in ref. 36) . Similarly to our approach, the direct genetic modification of islets before transplantation has also been explored in studies aiming at improving islet function by expression of heme oxygenase (HO-1), downregulation of protein tyrosine phosphatase using siRNA, or prevention of β-cell death by overexpression of viral proteins (Epstein-Barr virus vIL-10, baculovirus p35, and the adenovirus gp19 and RID α/β). [37] [38] [39] [40] However, studies illustrating the feasibility in human islets are rare but efficient thereby lentivirus-mediated expression of cFLIP in as little as 10% of the human islet cells was sufficient to protect these cells from IL-1β, TNF-α, and IFN-γ proinflammatory cytokines treatment. 41 Herpesviruses have the capacity to establish a lifelong infection of their host, a phenomenon associated with the expression of proteins with potent immunosuppressive properties, eluding CD8 + and CD4 + T cells, natural killer cells and innate immunity. 42, 43 Among the different immunevasins, US2 is extremely effective in targeting MHC-I molecules for destruction. Shortly after their synthesis, most of the newly generated MHC class I heavy chains are degraded. 24, 44 US2 has been suggested to downregulate all HLA-A and -G and most HLA-B alleles, whereas several HLA-B alleles and all HLA-C and -E alleles are likely to be insensitive to US2-mediated degradation. Importantly, the fact that US2 does not downregulate HLA-E may be useful in the context of immune protection, as HLA-E serves as an inhibitor of natural killer cells.
We confirmed that US2 expression induces downregulation of class I in surrogate β cells and that its coexpression with serine protease inhibitor 9 protects human islet cells against autoreactive T cells. The possible risk of increased susceptibility to natural killer cells associated with MHC-I downregulation could be counteracted with Serpin-9 coexpression by blocking granzyme B activity. 45 The significance of Serpin-9 in protecting β cells against PPI autoreactive T cells has been recently reinforced by a study showing that cytotoxic degranulation is the predominant modus operandi of PPI-CD8 + -mediated killing. 46 Environmental factors including proinflammatory cytokines might influence CTL killing capacity and β-cell survival during transplantation. The clinical transplantation setting where islets are directly infused via the portal vein might complicate the problem. 15 Participation of proinflammatory cytokines, instant bloodmediated immune response and activated complement or β-cell stress on autoreactive CTL killing capacity and on β-cell antigenic peptide generation remains to be investigated.
The use of NSG mice allowed us to monitor the human islet survival in mild hyperglycemic environment (basal glucose level is about 1 mmol/l higher in mouse than human) to specifically evaluate autoreactive CTL activity without interference from innate immunity and natural killer activity. 47 The killing assay using human pseudoislets and a human autoreactive T-cell clone isolated from recent onset patient with type 1 diabetes, although not relevant for a long term study of the graft, provides a suitable model to determine the fate of human islet cells in the context of human CD8 autoreactivity. The results prove that these cellular aggregates remained functional and glucose-responsive, indicating that they were capable of resisting autoimmune T cells.
The lentiviral system used to deliver the protective transgenes is believed to provide a long term expression of US2/Spi9. However, cessation of transgene expression, due to promoter silencing, is still possible, and could lead to eradication of the modified cells by immune system. The cytomegalovirus promoter, used here, is very active in finally differentiated cells, like β cells but as many viral promoters its expression could be silenced. 48 When translated to the clinic, other promoter, in particular cellular promoters, should be envisaged (Ubiquitin C promoter for example) and included in a specific comparative study.
To summarize, the novelty of our report is threefold. First, we engineered a novel assay to assess specific, autoimmune-mediated destruction of primary human β cells, allowing for the definition of selective β-cell loss in vitro. This approach facilitates the creation of a screening platform for identification of new compounds that inhibit the interplay between β cells and autoreactive T cells. Second, we designed a preclinical humanized mouse model to allow assessment of the fate of primary human β cells in an autoimmune environment. Finally, we showed that lentiviral vectors represent an efficient system for gene transfer into human diploid islet cells that can be subsequently reaggregated into functional pseudoislets. (4, 11, and 19 days) . Data are represented as scatter plot showing every glucose tolerance test results (a total of 9 values from bleeding at day 4, 11, and 19 for insulin and a total of 6 values from bleeding at day 11 and 19 for C-peptide). NT mice were used as negative control (n = 2). **Statistically significant; ***extremely statistically significant. CTL, cytotoxic T lymphocyte; GFP, green fluorescent protein; PPI, peptide of the preproinsulin; NT, non-transplanted. This offers new possibilities for genetic modification as a means of protecting human islet cells against the effect of autoreactive and possibly alloreactive T cells. By targeting two molecular pathways (viz. MHC class I synthesis and the perforin cell death pathway), we could increase the resilience of human β cells to acute, antigen-specific autoimmune attack. This study constitutes a proof of concept in mild hyperglycemic condition. The questions of the protective effect in extreme hyperglycemic environment where the increase in insulin production (and by definition the increase of antigenic leader peptide epitope) could exacerbate CTL killing, the scaling up of gene transfer techniques under clinically applicable procedures, the stability of transgene expression, the efficacy of downregulation of different HLA haplotypes and the risk of tumor development remain to be addressed before any translational research. Yet we can speculate that this type of approach could be successfully extended to protect against any auto-and alloreactivity. A combine approach using other highly potent viral immune evasion proteins could be envisaged to specifically target the HLA type or to increase the level of protection. 21 The next Holy Grail will be the translation of these evasion strategies without the use of viral carrier nor prior disruption of the islet integrity.
Pseudoislets formation. Dissociation of primary human islets was performed by 5-10 minutes 0.05% trypsin treatment at 37 °C. After washing step in DMEM + 10% fetal calf serum (Invitrogen, Karlsruhe, Germany) containing media, dissociated cells were passed though a 40 μm filter and seeded in ultra-low attachment six-well plates at ~200.000 cells/ml (Corning, NY 14831). Spontaneous reaggregation of islet cells started to be observed 24 hours after dissociation. Pseudoislets were maintained 6 days in culture prior reimplantation and medium was refreshed every 2 days.
Mice. Male NOD SCID IL-2R −/− mice (NSG) of 6-12 weeks old were obtained from the Jackson Laboratory (Bar Harbor, ME), and bred in the animal facilities of the Leiden University Medical Center. Animals were housed under specific pathogen-free conditions. All studies were approved by the local Animal Care Committee.
Human islets/pseudoislets transplantation. Islet equivalents of 3,000 and 5 × 10 6 dispersed and reaggregated islet cells, either non-transduced or GFP transduced, were transplanted under the left kidney capsule, using a polyethylene catheter and precision syringe (Hamilton, Reno, NV). Grafts were removed 19 days after transplantation. Formalin-fixed paraffin-embedded sections were stained for insulin and DNA content. Insulin and DNA staining, and GFP epifluorescence were assessed by confocal microscopy. Evaluation of PPI-specific CTL killing in vivo was performed by cotransplantation of 5 × 10 6 reaggregated cells, either GFP or US2/Spi9 transduced, with HLA-A2 PPI-directed cytotoxic T cells at a 100:1 target:effector ratio. Islets isolated from three different donors have been genetically modified by GFP or US2/Spi9 lentiviral vectors and transplanted under the kidney capsule of three different NSG mice. Islet functionality was evaluated after Intraperitoneal Glucose Tolerance Test by human insulin and C-peptide measurement.
Immunostaining and confocal microscopy. Intact islets or pseudoislets were fixed in PBS containing 4% paraformaldehyde. Permeabilization was performed using PBS/1% Triton. Blocking was done with PBS/BSA 3%, and first and secondary antibodies were diluted in PBS/BSA 3%. Anti-Insulin (H86; Santa Cruz Biotechnology) was used at 1:200 and secondary antibody coupled to Alexa 568 was used at a dilution of 1:500. Nuclei were stained with 4′-6-diamidino-2-phenylindole (DAPI). Samples were subjected to optical sectioning using a laser scanning confocal microscope (Zeiss, Thornwood, NY).
Glucose-induced insulin-secretion test.
Intact islets or pseudoislets were washed in PBS and transferred to a 8 μm pore size transwell plate (Corning HTS Transwell-96 well, Sigma-Aldrich) and preincubated in a modified Krebs-Ringer Bicarbonate buffer (KRBH) containing 115 mmol/l NaCl, 5 mmol/l KCl, 24 mmol/l NaHCO 3 , 2.2 mmol/l CaCl 2 , 1 mmol/l MgCl 2 , 20 mmol/l HEPES, 2 g/l human serum albumin (Cealb, Sanquin, The Netherlands), pH 7.4 for 2 hours. The transwell plate was then successively transferred for 1 hour to KRBH with 2 mmol/l and 20 mmol/l glucose at 37 °C. Insulin concentrations were determined in the supernatants by ELISA (Mercodia, Uppsala, Sweden).
Intraperitoneal glucose-tolerance test.
For the intraperitoneal glucosetolerance tests, mice were fasted overnight and injected with 2 g/kg glucose 1 mol/l i.p. blood was drawn from the tail vein at t = 0, t = 30 and t = 45 minutes. Intraperitoneal Glucose Tolerance Test was validated by determination of blood glucose concentrations measured using a glucose meter (Accu Chek, Roche). Human insulin content and human C-peptide concentrations were determined by ELISA according to the manufacturer's instructions. (Human insulin ELISA 10-113-10 and human C-peptide ELISA 10-1136-01; Mercodia, Uppsala, Sweden).
Statistical analysis.
All data were presented as mean ± SD. For human insulin and human C-peptide values presented in Figure 6 , data were subjected to nonparametric statistical analysis using two-way analysis of variance test with Bonferroni correction using GraphPad Prism software (GraphPad, San Diego, CA). A value of P < 0.05 was considered statistically significant. Figure S1 . CTLs killing capacity. Figure S2 . Effect of US2/Spi9 on islets functionality. Data. CTL killing assay.
SUPPLEMENTARY MATERIAL
